The osteoporosis and fracture risk for over the counter (OTC) proton pump inhibitors (PPIs) has been revoked by the FDA

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1345, 2011-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Availability of triptans over-the-counter (OTC) for the treatment of migraine has advantages and disadvantages

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 24, Iss. 8, 2008-08 ,pp. : 22-23

Adis International

Access to resources Recommend Favorite

Proton Pump Inhibitors and Fracture Risk: True Effect or Residual Confounding?

By Bodmer Michael   Meier Christian   Kraenzlin Marius E.   Meier Christoph R.  

Drug Safety, Vol. 33, Iss. 10, 2010-10 ,pp. : 843-852

Adis International

Access to resources Recommend Favorite

The EMA's Pharmacovigilance Working Party (PhVWP) is recommending that labels for proton pump inhibitors (PPIs) be updated

By  

Reactions Weekly, Vol. 1, Iss. 1397, 2012-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

PPIs, fracture risk and bone mineral loss

By  

Reactions Weekly, Vol. 1, Iss. 1259, 2009-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

PPIs linked to hip fracture, higher risk in smokers

By  

Reactions Weekly, Vol. 1, Iss. 1388, 2012-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite